6-tert-butyl-4-(4-nitro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile | 894078-17-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-tert-butyl-4-(4-nitro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile
• 英文别名: 6-tert-butyl-4-(4-nitrophenyl)-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 894078-17-2
• 化学式: C₁₆H₁₅N₃O₃
• 分子量: 297.313
• InChiKey: VCSRBPOZBMVVOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  98.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-tert-butyl-4-(4-nitro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile 在 吡啶 、 乙醇 、 水 、 tin(ll) chloride 作用下， 以 丙醇 、 二氯甲烷 为溶剂， 反应 23.0h， 生成 N-[4-(3-amino-6-tert-butyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-phenyl]-2-phenyl-acetamide
  参考文献：
  名称：

  WO2007/144203

  摘要：

  公开号：
• 作为产物：
  描述：

  频哪酮 、 对硝基苯甲醛 、 氰乙酸乙酯 在 ammonium acetate 作用下， 以 乙醇 为溶剂， 反应 17.0h， 以34%的产率得到6-tert-butyl-4-(4-nitro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile
  参考文献：
  名称：

  Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them.

  摘要：

  该发明涉及根据通式（1）所示的取代吡唑吡啶化合物：其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q如权利要求中所定义的，以及其盐，包括所述取代吡唑吡啶化合物的药物组合物，制备所述取代吡唑吡啶的方法，以及用于制造用于治疗血管生长失调疾病或伴随血管生长失调的疾病的药物组合物的用途，其中这些化合物有效干扰Tie2信号传导。

  公开号：

  EP1867648A1

文献信息

• Pyrazolopyridines, their preparation and their medical use
  申请人：Schering Aktiengesellschaft

  公开号：EP1683796A1

  公开（公告）日：2006-07-26

  The invention relates to pyrazolopyridines according to the general Formula I and the salts thereof, to pharmaceutical compositions comprising the pyrazolopyridines and to a method of preparing the pyrazolopyrimidines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

  该发明涉及按照一般式I及其盐制备的吡唑吡啶类化合物，包括含有该吡唑吡啶类化合物的药物组合物，以及制备该吡唑吡啶类化合物的方法，以及将其用于制造用于治疗血管生长失调疾病或伴随血管生长失调的疾病的药物组合物的用途，其中这些化合物有效干扰血管生成素，从而影响Tie2信号传导。
• Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
  申请人：Schwede Wolfgang

  公开号：US20060252754A1

  公开（公告）日：2006-11-09

  The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

  该发明涉及通式（I）的吡唑吡啶及其盐，包括含有该吡唑吡啶的制药组合物以及制备该吡唑吡啶的方法，以及将其用于制造用于治疗异常血管生长疾病或伴随异常血管生长的疾病的药物组合物的用途，其中该化合物有效地干扰血管生成素并因此影响Tie2信号传导。
• SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20080058326A1

  公开（公告）日：2008-03-06

  The invention relates to substituted pyrazolopyridines according to the general formula (I): in which A, B, D, E, R a , R 1 , R 2 , R 3 , R 4 , R 5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及一般式（I）的取代吡唑吡啶化合物，其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q如权利要求所定义，并且其盐，以及包括所述取代吡唑吡啶化合物的制药组合物，制备所述取代吡唑吡啶化合物的方法，以及将其用于制造治疗失调血管生长疾病或伴随失调血管生长的疾病的制药组合物的用途，其中这些化合物有效地干扰Tie2信号传导。
• SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20080064707A1

  公开（公告）日：2008-03-13

  The invention relates to substituted arylpyrazolopyridines according to the general formula (I): in which A, B, D, E, R a , R 1 , R 2 , R 3 , R 4 , R 5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted arylpyrazolopyridines, to methods of preparing said substituted arylpyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及一种按照通式(I)所示的取代芳基吡唑吡啶化合物，其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q的定义如权利要求书中所述，以及其盐。本发明还涉及包含所述取代芳基吡唑吡啶化合物的药物组合物，制备所述取代芳基吡唑吡啶化合物的方法以及其用于制造用于治疗失调的血管生长或伴随失调的血管生长疾病的药物组合物的用途，其中该化合物有效地干扰Tie2信号传导。
• 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
  申请人：Schwede Wolfgang

  公开号：US20090030010A1

  公开（公告）日：2009-01-29

  This invention relates to compounds of general formula I in which R 1 and R 2 are described in this application, the use of the compounds of general formula I as inhibitors of protein tyrosine kinases for treatment of various diseases as well as the compounds of general formulas II and III as intermediate compounds for the production of compounds of general formula I, whereby X, R 1a and R 2a have the meaning that is described in general formulas II and III.

  本发明涉及一般式I的化合物，其中R1和R2在本申请中被描述，一般式I的化合物用作蛋白质酪氨酸激酶的抑制剂以治疗各种疾病，以及一般式II和III的化合物作为一般式I的化合物的中间体化合物的使用，其中X，R1a和R2a具有在一般式II和III中描述的含义。